Introduction & Objective: Type 1 diabetes (T1D) remains associated with substantial clinical burden and long-term medication use. We assessed medication use in adults with T1D in US clinical practice.
Methods: We identified data (Merative MarketScan® Jan 1, 2014-Jun 30, 2019) for adults (≥18 years) with prevalent T1D (≥2 T1D claims ≥30 days apart, and either a T1D:T2D diagnosis code ratio >0.5 with prescribed glucagon/no oral hypoglycemic agents [excluding metformin] or a prescribed urine acetone test, prior to Jan 1, 2017 [index]). Clinical characteristics and medication use during the 12-month pre-index period were recorded.
Results: Compared with patients on Commercial plans, those on Medicare and Medicaid generally had higher comorbidity burden (Table). Insulin was the most frequently used medication across health plans. Patients on Commercial plans often received atorvastatin, lisinopril and metformin, but less frequently than with other health plans. Patients on Medicare plans patients frequently received atorvastatin, furosemide, lisinopril, and amlodipine. Patients on Medicaid plans frequently received acetaminophen/hydrocodone, lisinopril, and gabapentin.
Conclusions: Compared with patients on Commercial plans, those on Medicare and Medicaid plans more frequently received non-insulin drugs relating to cardiovascular and neuropathic conditions, likely reflecting higher comorbidity in these patients.
Q. Li: None. T.A. Dex: Stock/Shareholder; Pfizer Inc. Employee; Sanofi. Stock/Shareholder; Viatris Inc., Teva Pharmaceutical Industries Ltd. L. Wilson: Employee; Sanofi. Stock/Shareholder; Sanofi.
Sanofi
